Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers

Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and survival benefit in a subgroup of patients, resulting in regulatory approval. However, several recent randomized phase III studies in gastroesophage...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundar, Raghav, Smyth, Elizabeth C., Peng, Siyu, Yeong, Joe P. S., Tan, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243739/
https://www.ncbi.nlm.nih.gov/pubmed/32500029
http://dx.doi.org/10.3389/fonc.2020.00763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243739/
https://www.ncbi.nlm.nih.gov/pubmed/32500029
http://dx.doi.org/10.3389/fonc.2020.00763

Ejemplares similares